Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on developing and commercializing proprietary pharmaceuticals that improve the treatment of cancer.

Cantex's pipeline has two product candidates in Phase II clinical development:

  • CX-01, a polysaccharide that is a new chemical entity, neutralizes the activity of proteins that play a role in the adhesion of leukemia stem cells to the protective bone marrow environment, and neutralizes the activity of platelet factor 4, a cytokine which suppresses and delays platelet recovery after chemotherapy. CX-01 is in Phase II clinical trials for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
  • Dicopp™ (formerly known as CX-02), a proprietary combination of disulfiram + copper, is in a Phase II clinical trial for recurrent glioblastoma and in a separate investigator-initiated clinical trial for metastatic castration-resistant prostate cancer, with plans to enter Phase II clinical trials for metastatic pancreatic cancer and metastatic non-small cell lung cancer in 2018, pending financing

 

Latest News

Spotlight

Cantex has two product candidates in Phase II clinical development:

CX-01:

  • A new chemical entity, derived from heparin, with very low anticoagulant activity, neutralizes the activity of heparin-binding proteins that play a role in the adhesion of leukemia cells to the protective bone marrow environment and neutralizes the activity of a protein that suppresses and delays platelet recovery after chemotherapy
  • In a completed pilot study, 100% of primary AML patients achieved a complete remission from a single cycle of CX-01 combined with standard “7 + 3” induction chemotherapy
  • A randomized, 75-patient, Phase IIb clinical trial, in which newly diagnosed AML patients receive standard “7 + 3” induction chemotherapy ± CX-01, has recently completed enrollment, with top-line results anticipated in 3Q 2018
  • An investigator-initiated Phase II clinical trial in patients with MDS is also currently underway, with top-line results anticipated in 2018

Dicopp™:

  • Proprietary combination of disulfiram + copper which has been extensively reported to have cancer stem cell killing mechanisms, including proteasome inhibition and inhibition of activity of DNA repair enzymes
  • Highly cytotoxic to cancer stem cells derived from patients with glioblastoma, pancreatic cancer, non-small cell lung cancer, and breast cancer
  • Currently being studied in Phase II clinical trial in recurrent glioblastoma at major U.S.cancer centers with topline results from this clinical trial expected in 2Q18
  • An investigator-initiated clinical study in metastatic castration-resistant prostate cancer is enrolling patients
  • Phase II clinical studies in metastatic pancreatic cancer and metastatic non-small cell lung cancer are expected to be initiated in 2018, pending funding
  • Cantex owns issued and pending intellectual property for Dicopp™
  • FDA has granted Orphan Drug Designation for Dicopp™ for glioblastoma; Dicopp™ is a 505(b)(2)product